Two death reports have been filed with the FDA, and both name a drug that isn't approved. Nobody has shown that drug caused either death, and that's why we're starting there. It's Wednesday, and you're listening to GLP-1 Daily. After that: Walmart's zero-dollar GLP-1s, and the catch that comes with them. Then a new journal paper clocks how fast the Wegovy pill caught on. Tap follow so the next episode finds you.
Daniel Gilbert, investigative reporter at CBS News:
The cases appear to be the first public accounts in the U.S. alleging that unauthorized use of retatrutide — or products claiming to contain it — played a role in a patient's death, though the details aren't verified and it is unclear whether the drug was to blame.
On Tuesday we covered Lilly going after the black market in retatrutide. This is the next chapter, and it's grim. CBS got the reports through a records request. In July, a forty-one-year-old woman with obesity went into cardiac arrest after using product from what the report calls an unreliable source. Then in September, a report says a forty-nine-year-old died after a licensed nurse convinced her to buy it from an online peptide vendor. I want to be as careful as the reporting is. These are adverse-event filings. CBS couldn't verify them, and the FDA won't say whether it has. The July report also notes the woman was drinking kava at the time. A filing like this is a reason to investigate, not a finding. Harvard's Pieter Cohen says the FDA should get hold of the actual vials and test them. Lilly's statement says both people were taking black-market retatrutide, and that the company has found products with too much, too little, or the wrong active ingredient. The number that stays with me is from America's Poison Centers. They logged eight hundred sixty-two retatrutide exposures in the three months ending in September. In the first three months of the year it was two hundred forty-nine. That's a lot of demand, and nobody is supervising it. If you or someone close to you is injecting a research-use-only vial, talk to a prescriber about it this week. An unapproved drug shouldn't be something you shop for.
Annika Kim Constantino and Laya Neelakandan, reporting for CNBC:
Walmart plans to cover more than 250 prescriptions, including some insulin, inhalers and GLP-1s for diabetes, at no cost to its employees, in 2027, the company confirmed to CNBC.
Free is a lovely word. Now read the next line. Ozempic and Mounjaro drop to zero dollars for people with type 2 diabetes, after a new prior authorization. For weight loss, Walmart still doesn't cover GLP-1s at all. CNBC puts that in context. Other large employers either don't cover these drugs for obesity or have recently dropped them to hold down costs. So on obesity Walmart is following the crowd, not breaking from it. For workers with diabetes, though, this is real money, and it comes from the biggest private employer in the country. Watch the paperwork, too. Becker's reports these drugs were already covered for employees with type 2 diabetes. What changes in 2027 is the price, which goes to zero, and a fresh prior authorization to get it. If you're on one of these now, ask your prescriber and HR what that new approval involves before enrollment closes. Enrollment closes November 6. Premiums on the starting plan go up a dollar fifty per pay period, to thirty-nine eighty, which Walmart says is a smaller increase than last year's. So about one point six million U.S. workers now get two very different answers at the same pharmacy counter, depending on whether the diagnosis is blood sugar or weight.
From Medscape Medical News, summarizing a paper published Monday in Annals of Internal Medicine:
Within 2 months of launch, the oral semaglutide pill surpassed 100,000 monthly new prescriptions. Tirzepatide took 4 months to reach that mark, and injectable semaglutide took 20 months.
Two months! That's the Wegovy pill, which launched in January. The part I find more interesting is that prescriptions for injectable semaglutide didn't fall. Total semaglutide prescriptions went up. The authors read that as the pill reaching additional patients rather than just converting people already on the shot. This is a grade of evidence I'm happy to see. It's independently published and peer-reviewed, from a Johns Hopkins team led by Yara Jelwan, using national retail pharmacy data from July 2020 through June 2026. No specific funding was reported. One disclosure to name: one author has consulted for and received grants from drugmakers, including the company that makes the pill. And the limitations are exactly where my questions are. The data is aggregated, so you can't follow individual patients or see who switched. It has nothing on coverage, denied claims or cash payments. So Tuesday's theory that cash-pay is behind the pill's growth? This paper can't confirm it or rule it out. Compounded semaglutide and tirzepatide aren't counted either. And even with the pill, total semaglutide prescriptions in June were still a little below tirzepatide's. If you're weighing a pill against a shot, that's a question for your prescriber. A prescription count can't answer it.
Spotted something we got wrong, or have a coverage question you'd like us to chase down? Write to glp1daily at lantern podcasts dot com. Every message gets read.
The show notes link to all three sources if you want the full reporting. That wraps today's GLP-1 Daily, and we'll be back tomorrow, Thursday. GLP-1 Daily is a Lantern Podcast.